Clinical Trials

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed

86 enrolled 17 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04209855 2025-08-27

MIRASOL

453 enrolled 18 charts 1 FDA

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EndocrineGynecologicNETThoracic

139 enrolled 14 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT00170573 2024-12-16

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

77 enrolled 9 charts

Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05261490 2024-11-19

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Phase 1/2 Terminated

10 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01696032 2024-08-27

SGI-110

120 enrolled 22 charts

Ovarian Neoplasms

NCT02606305 2024-06-14

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

264 enrolled 41 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

566 enrolled 40 charts

Ovarian Neoplasms

NCT02431559 2022-10-10

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

53 enrolled 22 charts

Ovarian Neoplasms

NCT02865811 2022-09-13

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

26 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01035658 2021-10-28

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase 1/2 Terminated

22 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03480750 2020-11-10

Trientine

18 enrolled 16 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02631876 2020-10-14

FORWARD I

366 enrolled 20 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02421588 2020-04-03

CORAIL

442 enrolled 33 charts

Ovarian Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

Classical hematologyGynecologic

97 enrolled 22 charts

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00913835 2019-09-26

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

125 enrolled 20 charts

Neoplasms, Ovarian Neoplasms

NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

581 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00720096 2018-01-02

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Phase NA Terminated

4 enrolled 8 charts

Ovarian Neoplasms

NCT00727961 2017-06-08

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

Phase 4 Completed

58 enrolled 10 charts

Ovarian Neoplasms

NCT00182767 2016-03-10

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

45 enrolled 8 charts

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms

NCT01840943 2015-12-23

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Phase 3 Terminated

32 enrolled 13 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Neoplasms, Ovarian Neoplasms

NCT00945139 2015-07-31

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

46 enrolled 11 charts

Ovarian Neoplasms

NCT00743431 2015-04-15

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

Completed

224 enrolled 6 charts

Ovarian Neoplasms

NCT00113607 2014-06-27

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

672 enrolled 14 charts

Ovarian Neoplasms

NCT00003896 2013-01-04

S9912 Combination Chemo in Stage III Ovarian Cancer,

68 enrolled 8 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00653328 2012-05-23

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Phase 2 Terminated

15 enrolled 10 charts